Interpreting tuberculin skin tests in a population with a high prevalence of HIV, tuberculosis, and nonspecific tuberculin sensitivity.
Understanding the epidemiology and clinical course of tuberculosis is hampered by the absence of a perfect test for latent tuberculosis infection. The tuberculin skin test (TST) is widely used but suffers poor specificity in those receiving the bacille Calmette-Guérin vaccine and poor sensitivity in individuals with human immunodeficiency virus (HIV) infections. TST responses for a target population in Harare, Zimbabwe (HIV prevalence, 21%), recruited in 2005-2006, were interpreted by using a separate calibration population in Harare, for which interferon-gamma release assays (enzyme-linked immunosorbent spot (ELISpot)) results were also known. Statistical fitting of the responses in the calibration population allowed computation of the probability that an individual in the target population with a given TST and HIV result would have tested ELISpot positive. From this, estimates of the prevalence of tuberculosis infection, and optimal TST cutpoints to minimize misdiagnosis, were computed for different assumptions about ELISpot performance. Different assumptions about the sensitivity and specificity of ELISpot gave a 40%-57% prevalence of tuberculosis infection in the target population (including HIV-infected individuals) and optimal TST cutpoints typically in the 10 mm-20 mm range. However, the optimal cutpoint for HIV-infected individuals was consistently 0 mm. This calibration method may provide a valuable tool for interpreting TST results in other populations.
Dodd
Peter J
PJ
Department of Infectious Disease Epidemiology, St. Mary's Medical School, Imperial College London, Norfolk Place, London W2 1PG, United Kingdom. peter.dodd@imperial.ac.uk
Millington
Kerry A
KA
Ghani
Azra C
AC
Mutsvangwa
Junior
J
Butterworth
Anthony E
AE
Lalvani
Ajit
A
Corbett
Elizabeth L
EL
D000293:Adolescent; D000328:Adult; D002648:Child; D015331:Cohort Studies; D004797:Enzyme-Linked Immunosorbent Assay; D015658:HIV Infections / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D055985:Latent Tuberculosis / Q000175:diagnosis* / Q000453:epidemiology* / Q000821:virology; D011237:Predictive Value of Tests; D015995:Prevalence; D015203:Reproducibility of Results; D012307:Risk Factors; D014374:Tuberculin Test; D015030:Zimbabwe
Clin Exp Immunol. 2007 Nov;150(2):238-44
17672869
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD000171
20091503
Am J Respir Crit Care Med. 2007 Mar 15;175(6):618-27
17170386
Clin Infect Dis. 2009 Feb 1;48(3):302-12
19123864
AIDS. 2006 Apr 4;20(6):915-21
16549977
Am J Respir Crit Care Med. 2007 Apr 1;175(7):737-42
17218620
AIDS. 2005 Nov 18;19(17):2038-41
16260914
Lancet. 2003 Apr 5;361(9364):1168-73
12686038
AIDS. 2003 May 2;17(7):1102-4
12700468
PLoS One. 2008 Jan 16;3(1):e1441
18197251
PLoS Med. 2006 Jul;3(7):e238
16796402
Clin Infect Dis. 2006 Sep 1;43(5):634-9
16886159
Tuber Lung Dis. 1995 Apr;76(2):114-21
7780092
Lancet. 2006 Mar 18;367(9514):926-37
16546541
J Infect Dis. 2007 Aug 15;196 Suppl 1:S52-62
17624827
Am Rev Respir Dis. 1969 Apr;99(4):Suppl:1-132
5767603
Int J Tuberc Lung Dis. 2009 Oct;13(10):1231-7
19793427
Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 2):S221-47
10764341
Ann Intern Med. 2008 Aug 5;149(3):177-84
18593687
Int J Tuberc Lung Dis. 2008 Aug;12(8):895-902
18647448
Am J Respir Crit Care Med. 2007 Mar 1;175(5):514-20
17158278
Chest. 2007 Jun;131(6):1898-906
17565023
Clin Infect Dis. 2009 Apr 1;48(7):954-62
19245343
Ann Intern Med. 2008 Dec 2;149(11):777-87
18936496
Respir Res. 2006 Apr 01;7:56
16579856
Am J Respir Crit Care Med. 1999 Jan;159(1):15-21
9872812
JAMA. 1999 Aug 18;282(7):677-86
10517722
BMC Infect Dis. 2007 Aug 28;7:99
17725839
Am J Respir Crit Care Med. 2008 May 15;177(10):1164-70
18276940